Search

Proguanil

It does this by inhibiting the enzyme, dihydrofolate reductase, which is involved in the reproduction of the parasite. … Proguanil is a prophylactic antimalarial drug, which works by stopping the malaria parasite, _Plasmodium falciparum_ and _Plasmodium vivax_, from reproducing once it is in the red blood cells.

Durvalumab

It was granted accelerated approval by the FDA in May 2017 [A192807] for the treatment of selected patients with locally advanced or metastatic urothelial carcinoma. … [A192789] Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture,[L12621] durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote

Plazomicin

Developed by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from [DB12604]. … It mediates the antibacterial activity by binding to bacterial 30S ribosomal subunit and inhibiting protein synthesis [FDA Label].

Finafloxacin

Finafloxacin is marketed by Novartis under the brand Xtoro™, and was approved by the FDA in December 2014. … Finafloxacin is a fluoroquinolone antibiotic indicated in the treatment of acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus.

Etofamide

Etofamide, under the brand name Kitnos, was marketed in Brazil by Pfizer but has been discontinued [L5617].

Gepotidacin

[A273755] By inhibiting two distinct bacterial enzymes, a lower potential for the development of resistance to gepotidacin is expected. … [L52680] In March 2025, gepotidacin was approved by the FDA for the treatment of uncomplicated urinary tract infections in select patients.

Phenoxymethylpenicillin

An orally active naturally penicillin, phenoxymethylpenicillin is used to treat mild to moderate infections in the respiratory tract, skin, and soft tissues caused by penicillin G­-sensitive microorganisms … While there have been no controlled clinical efficacy studies that were conducted, phenoxymethylpenicillin has been suggested by the American Heart Association and the American Dental Association for use

Zinc acetate

Bevacizumab

[A193272,A193275,L12648] Avastin was subsequently approved by Health Canada on March 24, 2010 and by the European Commission on April 21, 2021. … [A192834,A192888,A192837,A192891,A192894] Bevacizumab is a humanized monoclonal IgG antibody that inhibits angiogenesis by binding and neutralizing VEGF-A.

Palovarotene

It first garnered interest as a potential treatment for emphysema but was eventually recognized as a potential novel therapy for patients with FOP. … [L40010] On August 16, 2023, palovarotene was also approved by the FDA for the management of HO associated with FOP.[L47845]